SNCA and Parkinson disease: Notice that not all studies show that nanoparticles are modified with a ligand for specific targeting, as the drug used for reduction in certain molecules, such as Amyloid beta in Alzheimer’s or alpha-synuclein in Parkinson’s, is safe for the surrounding cells.